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Abstract
This study demonstrates deregulation of polycomb activity by the synovial sarcoma-associated SYT-SSX2 oncogene, also
known as SS18-SSX2. Synovial sarcoma is a soft tissue cancer associated with a recurrent t(X:18) translocation event that
generates one of two fusion proteins, SYT-SSX1 or SYT-SSX2. The role of the translocation products in this disease is poorly
understood. We present evidence that the SYT-SSX2 fusion protein interacts with the polycomb repressive complex and
modulates its gene silencing activity. SYT-SSX2 causes destabilization of the polycomb subunit Bmi1, resulting in
impairment of polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes. Silencing by
polycomb complexes plays a vital role in numerous physiological processes. In recent years, numerous reports have
implicated gain of polycomb silencing function in several cancers. This study provides evidence that, in the appropriate
context, expression of the SYT-SSX2 oncogene leads to loss of polycomb function. It challenges the notion that cancer is
solely associated with an increase in polycomb function and suggests that any imbalance in polycomb activity could drive
the cell toward oncogenesis. These findings provide a mechanism by which the SYT-SSX2 chimera may contribute to
synovial sarcoma pathogenesis.
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Introduction
The manipulation of chromatin organization is at the heart of a
plethora of biological processes. Many proteins which modify the
structure of chromatin during normal cellular events are often
deregulated in disease processes, including cancer. One group of
proteins involved in the stable and dynamic regulation of
chromatin heritable over successive cellular divisions is the
polycomb group (PcG) family of complexes [1]. PcG complexes
are implicated in the repression of gene transcription through
exquisite modulation of chromatin structure. They were originally
identified in Drosophila as repressors of Hox genes for posterior body
segmentation [2]. polycomb complexes are classically divided into
Polycomb Repressive Complex 1 (PRC1) and Polycomb Repres-
sive Complex 2 (PRC2) [1]. The PRC2 complex is comprised of
the subunits EZH2, EED and SUZ12. PRC2 promotes gene
silencing by associating with histone deacetylases and DNA-
methyltransferase 1 [3,4], and through methylation of histone H3
at lysine 27 (K27) [5,6]. Methyl-H3K27 in turn serves as a binding
platform for PRC1, composed mostly of PC2, HPH, Bmi1 and
Ring1A/B. PRC1 compacts chromatin and hinders its accessibil-
ity to transcriptional activators [7]. Moreover, the complex
between subunits Bmi1 and Ring1B (an E3 ligase) is implicated
in the monoubiquitination of histone H2A at lysine 119 (K119)
[8], a modification frequently detected in the promoters of
polycomb target genes. Polycomb silencing plays an important
role in cell fate determination, self-renewal in both embryonic and
adult stem cells, as well as X-chromosome inactivation [1]. These
processes result from polycomb suppression of key developmental
pathways, including Wnt and Notch [9–11].
Recent evidence implicates deregulation of polycomb function
in cancer promotion. A number of reports have described an
increase in the expression of polycomb complex proteins in various
malignancies; overexpression of Bmi1 in medulloblastoma [12],
EZH2 in advanced prostate cancer [13] and SUZ12 in colon
cancer [14]. These increases in protein level are thought to result
in the aberrant silencing of tumor suppressor genes that would
normally prevent carcinogenesis [15]. Conversely, several lines of
evidence suggest that a decrease in polycomb function can favor
tumor formation in the appropriate context. Downregulation of
polycomb complex proteins has been described in certain tumors;
these include reduced levels of Ring1B in germ cell tumors [16]
and a decrease in Mel18 (polycomb RING Finger) in some breast
cancers [17]. Additionally, many cancers, including leukemias and
colon cancers, are associated with reactivation of Hox genes, the
classical targets of polycomb silencing [18,19]. More directly, one
study determined that expression of a loss-of-function mutant of
the PRC1 component PC2 resulted in the cellular transformation
of fibroblasts [20]. Recently, a report demonstrated a reduction in
histone H2A monoubiquitination- a polycomb-induced post-
translational modification- in prostate cancer tumor samples
[21]. Much like gain-of-polycomb function effects, these studies
imply that perturbation of normal polycomb-mediated transcrip-
tion repression is involved in some aspect of tumorigenesis.
However, it remains to be seen whether any known oncogene can
directly influence polycomb silencing in a negative fashion.
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5060Synovial sarcoma is an aggressive soft tissue cancer that
typically afflicts young adults. This disease is characterized by a
persistent t(X;18)(p11;q11) translocation event that juxtaposes the
SYT (SYnovial sarcoma Translocated) gene on chromosome 18
with an SSX gene (either SSX1 or SSX2) on the X chromosome
[22]. The resulting chimeric product, SYT-SSX, generates a fusion
protein derived from both genes. The t(X;18)(p11;q11) rearrange-
ment is detected in greater than 95% of synovial sarcoma tumors
and is thought to play a crucial role in the genesis and progression
of this cancer [22]. Previous studies have revealed that SYT-SSX1
possesses inherent transforming activity in both cell culture systems
and nude mouse models [23]. The oncogenic capacity of SYT-
SSX2 was also demonstrated in a transgenic mouse model
whereby SYT-SSX2, expressed in Myf5 lineage myoblasts,
generated synovial sarcoma-like tumors with 100% penetrance
[24]. Recently, it was demonstrated that SYT-SSX2 disrupted
cellular positioning by remodeling the cytoskeleton and altering
both cytoarchitecture and microtubule stability. The former was
caused by activation of the ephrin pathway [25]. Despite these
recent advances in the understanding of the biological conse-
quences of the SYT-SSX chimeras, the specific mechanisms
through which they execute these functions are unclear.
The SYT-SSX fusion product and its wildtype SYT and SSX
counterparts are nuclear proteins believed to function as regulators
of gene expression. Several studies have confirmed an interaction
between the N-terminal domain of SYT (SNH; also present in
SYT-SSX) with the SWI/SNF family of chromatin remodeling
complexes [26–28] and the histone acetyltransferease p300 [29].
The specific contribution of SYT and SYT-SSX to chromatin
modification and the biological consequences of these associations
are currently unknown.
Recently, colocalization of both wildtype SSX and oncogenic
SYT-SSX with the nuclear aggregates of polycomb complexes was
reported [30]. A functional correlation between polycomb and the
oncogene was also described [31–37]. These associations suggest-
ed that SYT-SSX likely modulates polycomb gene silencing
function, an effect that could ultimately contribute to synovial
sarcoma pathogenesis. However, a specific description of the
functional consequence of SYT-SSX on polycomb repression is
lacking. In this report, we demonstrate and further characterize
the interaction between the SYT-SSX2 oncogene and the PRC1
polycomb complex. We also show that de novo expression of SYT-
SSX2 induces a significant depletion of Bmi1 protein, an effect
that is mediated at the post-translational level. Downregulation of
Bmi1 was associated with attenuated monoubiquitination of
histone H2A, a Bmi1-specific function. These events correlated
with derepression of a variety of polycomb target genes involved in
diverse cellular processes. These studies demonstrate for the first
time polycomb antagonism as one possible mechanism by which
SYT-SSX2 contributes to the epigenetic deregulation of normal
transcription. They show negative regulation of polycomb function
by a reputed oncogene and propose a novel paradigm regarding
polycomb silencing and cancer-related proteins.
Results
SYT-SSX2 colocalizes and associates with polycomb
components
Previous reports have demonstrated colocalization between
SYT-SSX and polycomb bodies, using Bmi1 and Ring1A as
markers of polycomb complexes. These studies suggested that an
interaction, whether direct or indirect, exists between these
proteins. Similarly, using a retroviral system that allowed
expression of SYT-SSX2 in U2OS cells (human osteosarcoma)
at levels similar to those detected in primary synovial sarcoma cells
(Syn1 cells- Figure 1A; in synovial sarcoma, SYT-SSX2 expression
is driven by the robustly active promoter of SYT), we were able to
detect substantial colocalization of SYT-SSX2 with the polycomb
protein Bmi1 (Figure 1B). U2OS cells were chosen for their shared
mesenchymal origin with synovial sarcoma tumors. Overlapping
distribution was most readily visualized in the Bmi1-containing
polycomb bodies, where approximately 86% of these subnuclear
structures were co-occupied by SYT-SSX2 aggregates. Colocali-
zation of SYT-SSX2 was also observed with the polycomb
complex component Ring1B (Figure 1B), where co-aggregation
was slightly higher (93%). the SYT portion of the chimera alone
(SYTdel8) failed to display significant colocalization (Figure 1B),
indicating that targeting to polycomb bodies required the presence
of the SSX2 component in the SYT-SSX2 fusion protein. Further
analysis confirmed that when expressed alone, the SSX2
component of the chimera is capable of localizing to polycomb
bodies. SSX2 was detected in 78% of Bmi1- and 75% of Ring1B-
containing foci (Figure 1B). These indirect immunofluorescence
experiments, in accordance with others, suggested that SYT-SSX2
might physically interact with polycomb complexes. We next
wanted to determine whether a direct interaction between SYT-
SSX2 and Bmi1 or Ring1B was responsible for targeting SYT-
SSX2 to polycomb foci. Using in vitro GST pull-down assays, we
detected specific binding between SYT-SSX2 and Ring1B
(Figure 1D) but failed to demonstrate a similar interaction with
the Bmi1 protein (Figure S1). These results suggest that SYT-
SSX2 colocalization with the Bmi1/Ring1B complex in polycomb
bodies is likely mediated by its direct binding to Ring1B. Further
characterization of the SYT-SSX2/Ring1B association is under-
way.
Loss of Bmi1 immunoreactivity in SYT-SSX2-infectants
During the Bmi1/SYT-SSX2 colocalization experiments, we
observed a substantial reduction in Bmi1, but not Ring1B,
fluoresecent intensity in SYT-SSX2-expressing cells (Figure 1 B
and C). This reduction in Bmi1 fluorescence was quantified by
MetaMorph software as approximately 50% of wildtype levels
(Figure 1C). There was an apparent loss of not only the Bmi1 pool
distributed diffusely throughout the nucleoplasm, but in the Bmi1
pool present in polycomb bodies as well. No change in the Bmi1
nuclear pool was observed in pOZ vector control and wildtype
SYT-infectants. We also noted that localization of SSX2 in the
Bmi1- and Ring1B-bearing foci was not accompanied by an
attenuation of the Bmi1 signal (Figure 1B). Interestingly, the
specific loss of Bmi1 immunofluorescence associated with SYT-
SSX2 expression was consistently accompanied by an apparent
decrease of Bmi1 protein levels on immunoblots of SYT-SSX2-
transduced cellular extracts, using the same Bmi1 monoclonal
antibody (Figure 2A). Conversely, the levels of other polycomb
complex subunits, such as Ring1B and YY1 in SYT-SSX2
infectants were unchanged (Figure 2B), highlighting the specificity
of this depletion effect for Bmi1. Consistent with the Bmi1
fluorescence signal, the singular expression of the SYT or the
SSX2 fragment present in the chimera (SYTdel8, SSX2) did not
affect Bmi1 protein levels (Figure 2C). Altogether, these results
suggest that the SSX2 domain targets SYT-SSX2 to polycomb
foci. However, its fusion to SYT is required to cause diminution of
Bmi1 cellular levels. This effect is therefore specific to the SYT-
SSX2 oncogene.
To gain a better insight into the decreased immunoreactivity of
Bmi1 in SYT-SSX2-infectants, we generated a series of truncation
mutants of SYT-SSX2 and expressed them in U2OS cells. The
first set of deletions, named SXdel1-del4 (Figure 3A), contained
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PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5060Figure 1. SYT-SSX2 associates with Polycomb complex proteins. (A) Equivalent protein levels of retrovirally expressed SYT-SSX2 (FLAG and
HA-tagged) in U2-OS cells and in a primary human synovial sarcoma cell line (Syn1). 100 ug of cellular lysate-derived protein was loaded in each lane.
SYT-SSX2 was visualized with the anti-FLAG tag antibody in U2-OS and with a SYT-specific antibody [SV11; 37] in Syn1 cells. (B) Colocalization of SYT-
SSX2 with Bmi1 and Ring1B. Cells infected with pOZ viral vector, SYT, SYT-SSX2, SYTdel8, and SSX2 (all FLAG and HA-tagged), were analyzed by
indirect immunofluorescence. Infected cDNAs (HA, red) and Bmi1 or Ring1B (green) were visualized individually and with merging of the two
channels (merge). The cytoplasmic HA staining in pOZ-infected cells is due to the generation of an irrelevant FLAG/HA-tagged peptide by the vector.
Image magnification was at 636. (C) Decrease in Bmi1 fluorescence in SYT-SSX2 expressing cells. U2OS cells infected with SYT-SSX2 were analyzed by
indirect immunofluorescence for SYT-SSX2 (HA; red) and Bmi (green). Image magnification was at 636. Average fluorescence (20 cells per replicate;
n=3) of Bmi1 was compared between SYT-SSX2-infectants and uninfected cells using MetaMorph software and plotted. (D) In vitro binding of Ring1B
to SYT-SSX2. Upper panel: GST, GST-Bmi1 and GST-SYT-SSX2 visualized by Coomassie staining. The asterisks (*) indicate full-length proteins. Lower
panel: autoradiography of in vitro-translated (IVT) Ring1B bound to GST-Bmi1 (positive control) and GST-SYT-SSX2. Lane 1 represents 10% of input IVT
Ring1B.
doi:10.1371/journal.pone.0005060.g001
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and SXdel2, corresponding to deletion of amino acids 1–35 of the
translocated SSX2 domain (Figure 3A), retained their ability to
colocalize with polycomb complexes (Figure 3B). Conversely,
mutants SXdel3 and SXdel4, which lack amino acids 35–78, lost
their association with polycomb bodies. This suggested that the C-
terminal 44 amino acids contain the region essential for
localization of SYT-SSX2 to polycomb complexes. We further
refined the mapping of SYT-SSX2- polycomb association by
creating smaller truncations within the C-terminal 44 amino acids
of SSX2; these mutants were designated SXdel5-del9 (Figure 3A).
Of these mutants, only SXdel5 retained its polycomb colocaliza-
tion ability (Figure 3B), suggesting that the C-terminal 34 amino
acids of SYT-SSX2 contain the polycomb association motif. This
C-terminal stretch lacks homology to any known protein-protein
interaction domains and represents a novel interface for
association with polycomb components or their interacting
proteins. Like its SXdel4 counterpart, mutant SXdel8 with
truncated amino acids 55–65 expressed poorly (Figure 3D),
suggesting that region maintains proper stability of SYT-SSX2.
As anticipated, expression of the SYT-SSX2 mutants that co-
localized with polycomb complexes (SXdel1, del2, and del5)
induced depletion of endogenous Bmi1 protein (Fig. 3B and D).
These same three mutants also exhibited a decreased Bmi1
fluorescence in their nuclei (Fig. 3C). The remaining SYT-SSX2
mutants that failed to be targeted to polycomb bodies had no effect
on Bmi1 cellular levels. Taken together, these experiments suggest
that SYT-SSX2 requires close association with polycomb
complexes in order to induce a decrease in Bmi1 immunoreac-
tivity.
Loss of Bmi1 immunoreactivity is due to a decrease in
Bmi1 protein stability
Several explanations can account for the decrease in Bmi1
signal intensity in SYT-SSX2 infectants observed on cellular
extracts immunoblots and by indirect immunofluorescence; these
include a decrease in the transcription of Bmi1, a decreased half-
life of Bmi1 protein and a post-translational modification that
impairs epitope recognition by the Bmi1 monoclonal antibody
used in our studies. We did not detect changes in Bmi1 mRNA
levels following transduction of SYT-SSX2 by both relative RT-
PCR (Figure S2) and real time RT-PCR (Figure 4A), arguing
against transcriptional inhibition as the mechanism for Bmi1
depleted signal. We then carried out three different studies to
ascertain whether the lack of Bmi1 immunoreactivity resulted
from decreased Bmi1 protein stability or a de novo Bmi1
modification. In the first experiment, U2OS cells were transduced
with Bmi1 cDNA that was fused to two copies of the polyoma
epitope tag (2PY-Bmi1). These cells were re-infected with either
pOZ retroviral backbone or SYT-SSX2 cDNAs and lysed
48 hours later. Immunoblotting for both the polyoma tag (2PY)
and Bmi1 revealed signal depletion in the SYT-SSX2-infectants
Figure 2. Loss of Bmi1 immunoreactivity following de novo
expression of SYT-SSX2. (A) Extracts derived from pOZ vector, SYT
and SYT-SSX2 cells were analyzed by Western blotting for levels of Bmi1
and alpha-tubulin (loading control). (B) Loss of immunoreactivity is
specific to Bmi1. pOZ and SYT-SSX2-infectants were lysed and
immunoblotted for Bmi1, Ring1B, YY1, FLAG (to detect ectopically
expressed proteins) and alpha-tubulin. (C) The decrease in Bmi1 signal
is a specific function of SYT-SSX2 chimera. Extracts from uninfected
cells, pOZ, SYT, SYT-SSX2, SYTdel8 and SSX2 were immunoblotted for
Bmi1, FLAG-tagged ectopically expressed proteins and alpha-tubulin.
The FLAG-tagged protein visualized in pOZ-infected cells is due to the
generation of an irrelevant FLAG/HA-tagged peptide by the vector. The
molecular weight of the SSX2 domain is ,10 Kd. For its detection we
ran the SSX2 lysates on a separate 18% SDS-PAGE system. The
remaining lysates were resolved on a 10% SDS-PAGE. U: uninfected
cells.
doi:10.1371/journal.pone.0005060.g002
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translational modification, since an epitope-masking modification
should not interfere with the ability of the polyoma tag antibody to
recognize tagged Bmi1. In another experiment, lysates from either
pOZ or SYT-SSX2-infected cells were blotted for endogenous
Bmi1 using both a monoclonal and a polyclonal Bmi1-specific
antibodies. Both antibodies revealed decreased Bmi1 levels in
lysates from SYT-SSX2-transduced cells (Figure 4B), again
negating the possibility of epitope-masking by a Bmi1 post-
translational modification. Moreover, mass-spectrometry analysis
of Bmi1 present in SYT-SSX2 cellular lysates failed to detect
phosphorylated, acetylated or methylated residues (data not
shown). In the final experiment, the half-life of 2PY-Bmi1 was
measured using pulse-chase experiments in both pOZ and SYT-
SSX2 infectants. Not surprisingly, Bmi1 in SYT-SSX2-expressing
cells exhibited accelerated degradation when compared to pOZ
control (Fig. 4C). We confirmed the correct identity of the
immunoprecipitated 2PY-Bmi1 by peptide competition studies
Figure 4. Loss of Bmi1 immunoreactivity in SYT-SSX2-infected cells results from depletion of the Bmi1 protein. (A) Real time RT-PCR of
Bmi1 in U2OS lysates expressing the indicated proteins. (B) Left panel: overexpressed polyoma epitope-tagged Bmi1 (2PY-Bmi1) was infected with
either SYT-SSX2 or pOZ backbone. Cell lysates were immunoblotted with Bmi1 antibody, then stripped and reprobed with an anti polyoma tag
antibody. Immunoblotting for alpha-tubulin was used as a loading control. Right panel: cell lysates of pOZ and SYT-SSX2-infected cells were
immunoblotted for either mouse monoclonal or rabbit polyclonal Bmi1 antibody. Immunoblotting for alpha-tubulin was used as a loading control.
(C) Densitometry plotting of pulse-chase analysis of 2PY-Bmi1 in pOZ and SYT-SSX2-infected cells. 2PY-Bmi1-expressing cells infected with pOZ and
SYT-SSX2 were labeled for 1 hr. with S
35–labeled Methionine and Cysteine. Labeled cells were chased at the indicated timepoints and
immunoprecipitated with a polyoma tag antibody. Immunoprecipitated 2PY-Bmi1 band intensities were quantitated by densitometry and plotted
with pOZ and SYT-SSX2 experiments indicated. Pulse-chase experiment was successfully replicated (n=2). (D) Immunoprecipitation studies
demonstrating the specificity of the immunoprecipitated 2PY-Bmi1 band used in pulse-chase analysis. Negative controls using polyoma peptide
blocking (lane 3), no antibody (lane 4) and naı ¨ve U2OS cells (lane 1) are indicated.
doi:10.1371/journal.pone.0005060.g004
Figure 3. Mapping of the Polycomb association region on SYT-SSX2. (A) Schematic of wildtype SYT-SSX2 and the truncation mutants
generated within the SSX2 region. (B) Immunofluorescent colocalization studies of the SYT-SSX2 truncation mutants (HA, red) and Bmi1 (green), with
merging of the two channels displayed as well. Also indicated is the average percentage of SYT-SSX2 (or mutant) proteins aggregating with
polycomb bodies (a minimum of 100 polycomb foci counted per replicate; n=3). Image magnification was at 636. (C) Plot of Bmi1 fluorescence in
U2OS cells expressing the SXdel mutants and the POZ control vector. Average fluorescence (20 cells per replicate; n=3) of Bmi1 was compared
between POZ- and SXdel-infectants. The Bmi1 fluorescence in the POZ nuclei was consistently equivalent to that of uninfected cells. Data analysis
was performed using MetaMorph software. (D) Loss of Bmi1 immunoreactivity correlates with association of SYT-SSX2 to polycomb complexes.
Western blotting of cells infected with indicated FLAG-tagged proteins using Bmi1, FLAG and alpha-tubulin-specific antibodies.
doi:10.1371/journal.pone.0005060.g003
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a half-life of Bmi1 at 13.1 hours in pOZ vector-infected cells and
4.9 hours in SYT-SSX2 expressants. These studies suggest that
decrease in Bmi1 protein stability is the contributing factor to
Bmi1 signal depletion in SYT-SSX2-infected cells. The decision to
use the 2PY-Bmi1 in the pulse-chase experiments was based on the
fact that expressed 2PY-Bmi1 exhibited similar behavior to that of
endogenous Bmi1 in SYT-SSX2 expressants and on the high
immunoprecipitating efficiency of the 2PY antibody (Figure 4B).
Expression of the SYT-SSX2 compromises the integrity of
Bmi1/Ring1B complex and impairs its function in histone
H2A ubiquitination
From our aforementioned colocalization experiments, it was
evident that at least a subpopulation of Bmi1 depleted in the
presence of SYT-SSX2 corresponded to locations that also
contained Ring1B (polycomb bodies). We thus wanted to confirm
whether the pool of Bmi1 apparently depleted in SYT-SSX2-
infectants corresponded to the functional population of Bmi1
normally complexed with Ring1B. The integrity of the Bmi1/
Ring1B interaction was therefore assessed by coimmunoprecipi-
tating (co/IP) Bmi1 from SYT-SSX2 and pOZ vector control
infectants using anti-Ring1B antibodies. Western blotting of these
co/IPs revealed that although equivalent amounts of Ring1B were
immunoprecipitated from vector and SYT-SSX2 expressing cells,
the quantity of Ring1B-interacting Bmi1 was substantially reduced
in SYT-SSX2 infectants (Figure 5A, lower panel).
The pronounced depletion of Bmi1 from the Bmi1/Ring1B
complex by SYT-SSX2 raised the possibility that some Bmi1-
mediated function related to polycomb silencing may be compro-
mised in the presence of SYT-SSX2. Bmi1 can contribute to
polycomb silencing through the facilitation of Ring1B-dependent
histone H2A ubiquitination [8]. The loss of Bmi1-Ring1B
association in the presence of SYT-SSX2 suggested that a
corresponding alteration in histone H2A monoubiquitination might
occur as a consequence. Toascertain whetherthe diminished Bmi1/
Ring1B association translated into a loss of H2A K119 ubiquitina-
tion, we performed Western blotting analysis to determine the global
levels of ubiquityl-H2A in SYT-SSX2-infectants versus controls.
Immunoblotting demonstrated that while the levels of total histone
H2A and tubulin were unchanged, those of ubiquitinated H2A were
dramatically reduced following ectopic expression of SYT-SSX2
(Figure 5B). Taken together, these results demonstrate a general loss
of Bmi1-specific histone-modifying function caused by SYT-SSX2-
mediated depletion of Bmi1.
Genomewide analysis of SYT-SSX2-infectants
demonstrates reactivation of polycomb target genes
The depletion of Bmi1 and the associated diminution of
ubiquityl-H2A provided evidence to support the notion that SYT-
SSX2 antagonizes polycomb silencing. Nonetheless, the definitve
means to demonstrate a reversion of polycomb-mediated tran-
scription inhibition is to examine whether expression of SYT-
SSX2 induces reactivation of polycomb-repressed genes. We
performed genomewide analysis of SYT-SSX2-infectants using
microarray technology to elucidate the gene expression patterns
altered by this oncogene. Hybridization of total RNAs derived
from SYT-SSX2 and pOZ vector-infectant transcripts to Affyme-
trix microarray platforms was performed and transcript changes
were expressed as Log2 ratios of SYT-SSX2 signal intensity to
pOZ control [where the Log2 ratio (x) represents 2
x fold increases
(or decreases) in transcript level]. Only differences of two-fold or
greater that recurred in both replicates were designated for further
analysis. Of the differentially expressed genes, 123 displayed
transcriptional upregulation whereas 33 demonstrated transcription-
al downregulation (Microarray of upregulated and downregulated
target genes by SYT-SSX2 is available upon request). Gene profiles
in SYT-SSX2-expressing cells repeatedly displayed changes in the
expression patterns of key proteins involved in cell cycle control,
signal transduction, cytoskeletal organization and transcriptional
regulation. Many corresponded to previously described SYT-SSX
targets (e.g. IGF2) or genes known to be differentially expressed in
synovial sarcoma [e.g. EPHB3, TLE3; 25].
In order to determine which of these genes correlated with
polycomb targets, the Affymetrix microarray data was compared
to another genomewide analysis performed by Lee et al., 2006,
[11] in human embryonic cells. These studies, which combined
chromatin immunoprecipitation of polycomb-bound promoters
with microarray analysis, were designed to determine polycomb-
binding regions across the genome. They identified approximately
8% of the human embryonic genome as binding to polycomb
complexes and these genes have been designated as putative
polycomb targets. In order to compare our SYT-SSX2-differen-
tially expressed genes with this genomewide study, we utilized the
Vanderbilt University run, web-based program called WebGestalt
(http://bioinfo.vanderbilt.edu/webgestalt/). This program was
used to perform bollean operations to determine what percentage
of SYT-SSX2-regulated transcripts corresponded to putative
polycomb targets. Of the 123 genes upregulated by SYT-SSX2,
33 of them (26%) represent polycomb- repressed genes. These
genes are listed in Table 1. This percentage of polycomb
reactivated genes represented a greater than 3-fold enrichment
over the percentage of genes (8%) that could be theoretically
detected by chance alone [11]. These data point towards a trend
in polycomb target gene transcript upregulation following ectopic
expression of SYT-SSX2.
Antagonism of polycomb by SYT-SSX2
To confirm the overlap between the SYT-SSX2 microarray
expression profile and the reported polycomb gene targets [11],
upregulated transcription of a representative group of shared
targets was validated by relative RT-PCR (Figure 5C). The effect
of SYT-SSX2 on the Ring1B/Bmi1 complex was further
characterized on a representative promoter- that of the NGFR
gene- by chromatin immuno-precipitation (CHIP). Our choice of
an appropriate target for such studies was based on the persistent
upregulation of NGFR in all the microarrays performed on SYT-
SSX2-expressing mesenchymal cells (Figure 5C and data not
shown). Our CHIP analyses confirmed that the NGFR promoter
is indeed a direct target of SYT-SSX2 (Figure 5D, upper panel).
They also established that while Ring 1B is present at the
promoter in vector control- and SYT-SSX2 expressants
(Figure 5D, middle panel), Bmi1 was no longer detected on the
NGFR region in SYT-SSX2 cells (Figure 5D, lower panel). These
results are consistent with the Ring 1B- and Bmi1- SYT-SSX2
colocalization data (Figure 1B) and Bmi1 diminution upon SYT-
SSX2 expression.
In summary, the SYT-SSX2 oncogene appears to influence
gene-expression programs through its association with and
subsequent antagonism of polycomb components in mesenchymal
cells. This function likely constitutes part of its transforming
activity in synovial sarcoma.
Discussion
In this study, we demonstrate a consistent and significant
depletion of the polycomb complex protein Bmi1 following de novo
SYT-SSX2 Antagonizes Polycomb
PLoS ONE | www.plosone.org 7 April 2009 | Volume 4 | Issue 4 | e5060expression of the SYT-SSX2 oncogene. This attenuation of Bmi1
appears to be mediated at the level of protein stability, although
the specific mechanism by which SYT-SSX2 promotes Bmi1
degradation awaits further investigation. The expected outcome of
Bmi1 degradation in the presence of SYT-SSX2 is the alteration of
at least certain aspects of polycomb silencing function. Indeed,
evidence exists to corroborate the expected impairment of
polycomb gene regulation. First, we demonstrated the predicted
loss of global histone H2A monoubiquitination resulting from
SYT-SSX2-mediated Bmi1 depletion. This effect most likely stems
Figure 5. Functional antagonism of Bmi1 in SYT-SSX2-expressing cells. (A) Lower panel: the Ring1B-interacting Bmi1 population is depleted
in SYT-SSX2-expressing cells. pOZ and SYT-SSX2 infected cell extracts were immunoprecipitated (IP) with a Ring1B antibody. Immunoprecipitates
were immunoblotted with the antibodies indicated to the left. FLAG antibody was used to detect ectopically expressed SYT-SSX2 (upper panel). (B)
Extracts from pOZ and SYT-SSX2 infectants were immunoblotted with anti-ubiquityl H2A, total H2A and FLAG antibodies. Immunoblotting for alpha-
tubulin was used as a loading control. (C) Increased transcription of SYT-SSX2-derepressed polycomb targets. Relative RT-PCR of a subset of SYT-
SSX2-upregulated genes also shown to be polycomb-silenced targets [11]. GAPDH served as loading control. D) SYT-SSX2 (upper image), Ring 1B
(middle image) and Bmi1 (lower image) occupancy on the NGFR promoter by CHIP-PCR in pOZ vector- and SYT-SSX2-expressing U2-OS cells.
doi:10.1371/journal.pone.0005060.g005
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towards H2A, as the population of depleted Bmi1 corresponded
largely to the pool that interacted with Ring1B. Whether the
reduction in Bmi1 alters the positioning of Ring1B relative to H2A
and/or affects the polyubiquitination status of Ring1B remains to
be elucidated. To date, this is the only specific polycomb function
that has been shown to be compromised by SYT-SSX2, suggesting
that only a subset of polycomb target genes may be affected by the
chimera.
In addition, we presented evidence to suggest that the Bmi1
depletion and histone H2A hypoubiquitination correlated with the
reactivation of polycomb-repressed genes. To demonstrate this
derepression, we adopted a genomewide approach that relied on
microarray analysis to determine which transcripts were induced
by SYT-SSX2. The output from these analyses were compared
with another study whereby polycomb target promoters were
identified utilizing a combination of chromatin immunoprecipita-
tion and microarray analysis. One important limitation of these
comparison studies is that the genomewide analysis conducted by
Lee et al. (2006), as well as others, were performed in the context of
embryonic stem (ES) cells. However, studies performed on a
prototypic polycomb target promoter –the NGFR gene- corrob-
orated our central observation of Bmi1 attenuation by SYT-SSX2.
Further chromatin studies in U2-OS and other mesenchymal cells
are ongoing.
Although the influence of indirect effects cannot be discounted
and unlisted genes may be down-regulated to undetectable levels,
the microarray results support the notion that SYT-SSX2 may
predominantly activate rather than suppress genes. Notably, a
large number (more than half) of the 33 derepressed polycomb
targets were also upregulated in the microarrays of the
SYT-SSX2-derived murine synovial sarcomas as well as human
synovial sarcoma tissues [23,32,33,34,35]. The overlap includes
either the same factors such as Jagged2 (JAG2), Delta-like 1
(DLL1), Sal-like 1 (SALL1), dual specificity phosphatase 9
(DUSP9), nerve growth factor receptor (NGFR), ephrin B3
receptor (EPHB3), suppressor of cytokine signaling 3 (SOC3),
Msh-homeobox 1 (MSX1), chromobox homolog 4 (CBX4),
BCL2-Like11 (BCL2L11), cytokine receptor-like factor 1
(CRLF1), member RAS family (RAB40), solute carrier family 16
(SLC16), nuclear factor of activated T-cells (NFATC1), or
members of the same signaling families such as JAG1, SALL2,
MSX2, transducin-like enhancer of split 3 (TLE3), G-protein
receptors (GPR), ephrin receptors (EPHB1,2,4), NFATC4,
CBX2,5, and platelet-derived growth factor (PDGF). Several of
the polycomb-silenced transcripts upregulated by SYT-SSX2
corresponded to proteins that are implicated in tumor formation
and progression. Several members of the Notch signaling pathway,
including DLL1, JAG2 and HES4, displayed increased steady state
mRNA in the presence of SYT-SSX2. Activating mutations of
Notch signaling receptors or overexpression of the Notch ligands
(DLL, JAG) have been observed in hematological, breast, cervical,
and intestinal tumors [38]. Increased Notch signaling can promote
cellular transformation, epithelial-to-mesenchymal transition and
tumor vascularization in the appropriate context. Another gene,
EphB3, corresponds to a receptor of the ephrin signaling pathway,
a cascade whose deregulation contributes to tumor cell shape,
adhesion, migration and angiogenesis [7]. Finally, PDGF-B
corresponds to a ligand in the platelet derived growth factor
pathway that can mediate tumor migration and capillary network
formation. Reactivation of these genes by SYT-SSX2 could
Table 1. Putative polycomb target genes reactivated by SYT-SSX2.
Locus
Link ID
Gene
Symbol Gene Name
Log2
Ratios
a
Locus
Link ID
Gene
Symbol Gene Name Log2 Ratios
3714 JAG2 Jagged 2 2, 2, 1.9, 1.9 387763 LOC387763 Hypothetical LOC387763 1, 1
6236 RRAD Ras-related associated with diabetes 3, 2.8, 3.4, 2.8 1852 DUSP9 Dual specificity phosphatase 9 1.3, 1.2
57801 HES4 Hairy and enhancer of split 4 2.4, 2.5 5979 RET Ret proto-oncogene 2.4, 2
9021 SOCS3 Suppressor of cytokine signaling 3 1.2, 1.1, 1.2, 1.1 7090 TLE3 Transducin-like enhancer of split 3 1.3, 1.3
4804 NGFR Nerve growth factor receptor 5.4, 5.4 9244 CRLF1 Cytokine receptor-like factor 1 3, 2.9
2049 EPHB3 EPH receptor B3 1.2, 1.2 54855 FAM46C Family with sequence similarity 46,
member C
3.3, 1.6, 3.3,
1.3
8913 CACNA1G Calcium channel, alpha 1G 1.8, 2 10018 BCL2L11 BCL2-like 11 1.2, 1.3
28514 DLL1 Delta-like 1 5.3, 5.4 30812 SOX8 SRY-box 8 6.5, 6.3
23345 SYNE1 Spectrin repeat containing, nuclear
envelope 1
1.3, 1.2 4616 GADD45B Growth arrest and DNA
damage-inducible 45
1.2, 1.1, 1, 1.1,
1.1, 1
284207 METRNL Meteorin 2, 2.2 8535 CBX4 Chromobox homolog 4 1.3, 1.4
5155 PDGFB Platelet-derived growth factor beta 4.1, 1.9, 3.4, 1.7 131583 FAM43A Family with sequence similarity
43, member A
3.3, 3.3
4772 NFATC1 Nuclear factor of activated T-cells 1.1, 1, 1.2, 1.1 6299 SALL1 Sal-like 1 1.2, 1.2
9123 SLC16A3 Solute carrier family 16, member 3 2.7, 2.6, 2.8, 2.5 2643 GCH1 GTP cyclohydrolase 1 1.4, 1.3
10966 RAB40B RAB40B, member RAS family 1.1, 1 4487 MSX1 Msh homeobox 1 1.4, 1.2
7107 GPR137B G-protein receptor 137B 1.1, 1 4062 LY6H Lymphocyte antigen 6 complex,
lo c u sH
1.9, 1
10568 SLC34A2 Solute carrier famiy 34, member 2 4.1, 4 816 CAMK2B Calcium/calmodulin-dependent
kinase 2
4.3, 4.2
164633 CABP7 Calcium binding protein 7 4.1, 4.1
aNonbolded log2 ratios represent hits in microarray replicate 1 bolded log2 ratios represent replicate 2.
doi:10.1371/journal.pone.0005060.t001
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gression in synovial sarcoma.
The finding that a reputed oncogene can suppress certain
aspects of polycomb silencing was somewhat unexpected. The
majority of work examining the role of polycomb silencing in
cancer has established that oncogenicity is often associated with a
polycomb gain of function. However, several lines of evidence,
including the observed reactivation of the polycomb target Hox
genes [19,21] and downregulation of some polycomb proteins in
limited cancers [16], have suggested that polycomb derepression
can equate to tumorigenesis in the appropriate context. In
addition, the transforming activity attained by a loss-of-function
mutant of the polycomb subunit PC2 provides more direct
evidence that polycomb silencing can also be impaired in cancer.
Recently, a landmark study also demonstrated that a consistent
decrease in global ubiquityl-histone H2A occurs in prostate
cancer, suggesting that H2A hypoubiquitination may serve as a
tumor marker in this disease [21]. The significance of the work
presented in the current study lies in the novel demonstration of
disrupted polycomb silencing caused by an oncogene.
A crucial and precarious balance in Polycomb function is
needed for maintaining the homeostasis of the cell. This balance in
polycomb gene silencing is mediated by processes including
histone H2A ubiquitination, chromatin compaction, RNA poly-
merase II inhibition, histone hypoacetylation and DNA methyl-
ation. When any of these functions are perturbed through a gain of
polycomb silencing, such as when polycomb components are
overexpressed, tumor-promoting phenotypes are induced through
the repression of tumor suppressors. However, a shift towards
impairment of certain polycomb silencing functions can also
promote cancer through the reactivation of oncogenic genes. In
this regard, it is important to emphasize that many polycomb gene
targets are overexpressed in cancer, including members of the
Wnt, Notch and ephrin signaling pathways [9–11]. Although it has
yet to be determined, a possible mechanism explaining aberrant
signaling through these pathways in cancer may reside in the
suppression of polycomb silencing.
Based on the available evidence, we believe that SYT-SSX2
protein is recruited to a subset of polycomb repressive complexes
within the nucleus via direct and/or indirect interactions with
polycomb components or other co-residing chromatin modifiers.
This SYT-SSX2 recruitment promotes the displacement and/or
degradation of Bmi1 protein, which alters normal Bmi1-mediated
functions, such as histone H2A monoubiquitination. In addition,
the SYT-SSX2 chimera, through physical interactions [29,30],
may recruit both the SWI/SNF chromatin remodeling complex
and p300 acetyltransferase to this polycomb-repressed chromatin.
The aberrant targeting of these proteins may then promote
changes that culminate in the transcription of genes that were once
silenced by polycomb complexes. The protein products of these
upregulated genes could then ultimately contribute to some aspect
of synovial sarcoma pathogenesis.
Taken together, these studies provide an interesting insight into
the molecular function of SYT-SSX2. When carried further, these
analyses of chromatin deregulation by the fusion protein will be
beneficial for targeting synovial sarcoma. Moreover, they will
enhance our understanding regarding the regulation of polycomb
components.
Materials and Methods
Cells and Reagents
The U2OS osteosarcoma cell line was maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Antibodies for Western blotting and
immunofluoresence included anti-Bmi1 (Upstate; Lake Placid,
NY), anti-Ring1B (MBL; Woburn, MA), anti-YY1 (Santa Cruz
Biotechnology; Santa Cruz, CA), anti-tubulin (Sigma; St. Louis,
MO), anti-ubiquitinated H2A (Upstate; Lake Placid, NY), anti-
H2A (Upstate; Lake Placid, NY) anti-HA (Sigma; St. Louis, MO)
and anti-FLAG (Sigma; St. Louis, MO). The SSX2-specific
polyclonal antibody and the SV11 monoclonal antibody were
described in Pretto et al, 2006 [39].
Plasmids
The SYT, SYTdel8, SYT-SSX2 cDNAs were inserted into the
pOZ retroviral construct (a gift from P. Nakatani) as described
previously [39]. Construction of pGST-SYT-SSX2 was previously
described [29]. The LZRS-Bmi12PY-IRES-GFP and pGST-Bmi1
vectors were kind gifts from M. Lohuizen. The pCS2
+-Ring1B
vector for in vitro translation of Ring1B was a gift from A.
Ciechanover. For construction of SYT-SSX2 deletion mutants,
designated SYT-SSX2del1-del9, site directed mutagenesis was
performed using pOZ-SYT-SSX2 as a template. Primers utilized
in the mutagenesis reactions were as follows: SYTSSXDel1F-59-
CCTTATGGATATGACCAGG-TGCCAGAAGCATCTGGC-
39; SYTSSXDel1R-59-GCCAGATGCTTCTGGCACCT-GGT-
CATATCCATAAGG-39; SYTSSXDel2F-59-GGAAATGATTC-
GGAGGAAAC-TACCTCTGAGAAGATT-39; SYTSSXDel2R-
59-AATCTTCTCAGAGGTAGTTTCC-TCCGAATCATTTC-
C-39; SYTSSXDel3F-59-TGCCCCCCGGGAAAACCACACA-
GA-CTGCGTGAGAGA-39; SYTSSXDel3R-59-TCTCTCAC-
GCAGTCTGTGTGGTTTTC-CCGGGGGGCA-39; SYTSSX-
Del4F-59-GAACATGCCTGGACCGGCCGCTGGAGG-AGA-
CTA-39; SYTSSXDel4R-59-TAGTCTCCTCCAGCGGCCGG-
TCCAGGCATGTT-C-39; SYT-SSXDel5F-59-TGCCCCCCG-
GGAAAACCAGGACCCAAAAGGGGGGA-AC-39; SYT-SSX-
Del5R-59-GTTCCCCCCTTTTGGGTCCTGGTTTTCCCG-
GGGGG-CA-39; SYT-SSXDel6F-59-TCTCTCACGCAGTC-
TGTGAGATCTCTCGTGAATCTT-39; SYTSSX-Del6R-59-
TCTCTCACGCAGTCTGTGAGATCTCTCGTGAATCTT-
39; SYTSSXDel-7F-59-TCTGGACCCAAAAGGGGGAGAAA-
ACAGCTGGTGATT-39; SYTSSXDel7R-59-AATCACCAGC-
TGTTTTCTCCCCCTTTTGGTCCAGA-39; SYTSSXDel8F-
59-GGGAACATGCCTGGACCATTTATGAAGAGATCAGC-
39; SYTSSXDel8R-59-GCTGATCTCTTCATAAATGGTCCA-
GGCATGTTCCC-39; SYTSSXDel9F-59-GAGAGAAAACAG-
CTGGTGGCGGCCGCTGGAGGAGAC-39; SYTSSXDel9R-
59-GTCTCCTCC AGCGGCCGCCACCAGCTGTTTTCTC-
TC-39.
Retroviral Transduction of U2OS Cells
The SYT, SYTdel8, SYT-SSX2 cDNAs were inserted into the
pOZ retroviral vector and the infections were conducted as
described previously [39].
RT-PCR
For RT-PCR analysis, total RNA was first extracted from
retrovirally-infected cells using the RNAeasy Miniprep Kit
(Qiagen). 1 mg of total RNA was subjected to reverse transcription
reaction using the Superscript II Reverse Transcription System
(Invitrogen). A 1 ml volume of the cDNA reaction was amplified
using PCR with the following specific primers, BMI1-F: 59-
GGTACTTCATTGATGCCACAAC-39, BMI1-R: 59-CTGC-
TGGGCATCGTAAGTATC-39, NGFR-F: 59-GGCACCTCCA-
GAACAA-GACCTC-39, NGFR-R: 59-ACAGGGATGAGGT-
TGTCGGTG-39, RRAD-F: 59-TTTA-CAAGGTGCTGCT-
GCTGGG-39, RRAD-R: 59-TGCCGCTGATGTCTCAAT-
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RET-R: 59-CCATGTGGAAGGGAGG-GCTC-39, PDGF-B F:
59-GATCCGCTCCTTTGATGATC-39, PDGF-B R: 59-
GTCTCA-CACTTGCATGCCAG-39, HES4-F: 59-CACCG-
CAAGTCCTCCAAG-39, HES4-R: 59-TCACCTCCGCCAGA-
CACT-39. IGF2-F: 59-GAAGTCGATGCTGGTGCTTCT-39,
IGF2-R: 59-TGAACGCCTCGAGCTCCTTG-39, DLL1-F: 59-
GTTCGAACTGAAGCT-GCAGGA-39, DLL1-R: 59-
AGAATCTGTGTGGAGAGCTTC-39, JAG2-F: 59-AAGAC-
CTGAACTACTGTGGCA, JAG2-R: 59-GCATGGCTTCCCT-
TCACACT-39, EPHB3-F: 59-GGTGACGTCTGAGCTGG-
CATG-39, EPHB3-R: 59-TCATCTGGCGCAATGGTG-TCC-
39. GAPDH loading control was amplified using the following
primers, GAPDH-F: 59-TGATGACATCAAGAAGGTGGT-
GAAG-39 and GAPDH-R: 59-TCCTTGGAGG-CCATGTGG-
GCCAT-39. Reaction conditions for PCR amplification are as
follows: 1 cycle of 4 min. at 94uC; 32 cycles of 1 min. at 94uC,
1 min. at 56uC and 1 min. at 72uC; 1 cycle of 10 min. at 72uC.
In vitro Binding Assays
The generation of GST, GST-p300-CH3, GST-Bmi1 and
GST-SYT-SSX2 lysates was performed as previously described
[28]. In vitro translation of SYT-SSX2 and Ring1B was carried out
using the coupled TnT rabbit reticulocyte in vitro transcription/
translation system (Promega Co; Madison, WI). Transcription/
translation was carried out in the presence of SP6 RNA
polymerase and 20 mCi S
35-methionine. Binding reactions of in
vitro translated proteins and GST-fused proteins were performed in
the presence of binding buffer (20 mM Tris pH 8.0, 100 mM
NaCl, 0.1% NP-40, 1 mM DTT) for 1 hr. at 4uC. Beads were
washed in ice-cold binding buffer 3 times, then boiled in Laemmli
sample buffer. Reactions were electrophoresed on a 10% SDS-
polyacrylamide gel, dried and exposed to x-ray film for
autoradiography.
Indirect Immunofluorescence
For indirect immunofluorescence studies, coverslips were fixed
in 3% paraformaldehyde/ 2% sucrose, washed with PBS and
permeabilized in 0.2% Triton X-100. Cells were blocked in 3%
goat serum and incubated with anti-Bmi1 (1:100), anti-Ring1B
(1:100) and anti-HA (1:200) antibodies for 2 hrs, then with Alexa-
conjugated secondary antibodies (Molecular Probes; Eugene, OR)
for 30 min. Cells were visualized using a Zeiss (Axioplan 2)
fluorescence microscope.
Microarray Analysis
Total RNA was extracted from infected NIH3T3 cells using the
RNAeasy Miniprep Kit (Qiagen; Valencia, CA) according to the
manufacturer’s instructions. For microarray experiments, RNA
was submitted to the Vanderbilt Microarray Shared Resource
Facility for hybridization with Affymetrix Human Genome U133
GeneChip arrays. Gene expression intensity changes were
expressed as Log2 ratios of SYT-SSX2 signal intensity to pOZ
control [where the Log2 ratio (x) represents 2
x fold increases (or
decreases) in transcript level]. Analysis of microarray data was
carried out by the WebGestalt Program, maintained by Vanderbilt
University and available online at http://bioinfo.vanderbilt.edu/
webgestalt/.
Lysis and Immunoprecipitations
To generate extracts for Western blotting analysis of ubiquiti-
nated H2A, infected cells were lysed and boiled directly in Laemmli
sample buffer. Lysate preparation for immunoprecipitation and
other Western blotting procedures were performed in IP buffer
(50 mM Tris pH 8.0, 250 mM NaCl, 0.5% NP-40 and protease
inhibitor cocktail). Lysates used for immunoprecipitation were
incubated with primary antibodies (all at 1 mg/mL final
concentration) for 4 hrs at 4uC. Samples were then incubated
with Protein G-sepharose (Amersham Biosciences; Uppsala,
Sweden) for 30 min at 4uC. Immunoprecipitates were then
washed in IP buffer and boiled in Laemmli sample buffer for
Western blot analysis.
Pulse Chase Experiments, Peptide Blocking and
Regression Analysis
U2OS cells that stably expressed 2PY-Bmi1 were infected with
pOZ and SYT-SSX2 vectors as described earlier. At 48 hrs post-
infection, cells (2610
5 cells per timepoint for each experimental
condition) were starved in Methionine-minus DMEM medium
(containing 5% dialyzed fetal bovine serum) for 1 hr at 37uC. Cells
were then labeled with 500 mCi of S
35 labeled Methionine/
Cystine diluted in Methionine-minus medium (containing 5%
dialyzed fetal bovine serum) for 1 hr at 37uC. Cells were then
chased at indicated time-points with Methionine-positive DMEM
supplemented with 10% fetal bovine serum. Cells from each
timepoint were processed and immunoprecipitated with anti-
polyoma tag antibody (1 mg/mL) as described before. Immuno-
precipitates were run on 10% polyacrylamide gels, which were
subsequently dried and exposed to x-ray film for autoradiography.
Immunoprecipitated 2PY-Bmi1 was quantitated using densitom-
etry computer software (FluorChem 9800; Alpha Innotech, San
Leandro, CA). To confirm the correct identity of the immuno-
precipitated 2PY-Bmi1 species, 1610
6 cells were labeled overnight
with S
35 labeled Methionine/Cystine. Cells were immunoprecip-
itated with anti-polyoma antibodies as before, except that the
following conditions were included: naı ¨ve U2OS cells, no antibody
control, preclearing of lysate with Sepharose beads (30 min. at
4uC) and overnight preincubation of polyoma antibody with
polyoma epitope tag peptide (20 mg/mL; Covance, Emeryville,
CA). For the regression analysis, densitometry values for pOZ and
SYT-SSX2 were plotted on GraphPad Prism software (GraphPad
Software Inc., La Jolla, CA) for linear regression analysis and half-
life calculations. Half-lives were assessed by determining the
unpaired half-life time-point values from a relative intensity value
of 0.5.
Chromatin Immuno-Precipitation
CHIP was performed on pOZ- and SYT-SSX2-derived nuclear
lysates according to the protocol described by Boyer et al. [40].
2610
7 cells were used for each IP reaction. After DNA
precipitation, PCR of the NGFR promoter region was performed
with the following primers: NGFR-forward: 59-GCAGTTAGG-
GAGCAAGGCTCC-39 and NGFR-reverse: 59-GGTGGGA-
AGCAGAGGCAAAGG-39. SYT-SSX2 was IP’ed with the
SSX2-specific antibody described in Pretto et al. [39]. For Ring1B
and Bmi1 CHIP, the MBL and Upstate antibodies described
above were used, respectively.
Supporting Information
Figure S1 In vitro binding assays
Found at: doi:10.1371/journal.pone.0005060.s001 (0.54 MB
DOC)
Figure S2 SYT-SSX2 does not alter Bmi1 mRNA levels
Found at: doi:10.1371/journal.pone.0005060.s002 (0.10 MB
DOC)
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